SQZ’s Point-of-Care (POC) Manufacturing Platform Shows Promising Results with Ability to Produce Cell Therapies at Scale in Under 10 Hours WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: ...

Since COVID-19 emerged late last year, there's been an enormous amount of research produced on this novel coronavirus disease. But the content publicly available for this data and the format in which ...

Perspective Therapeutics announced data presentations at ASCO 2025 for its cancer treatment programs [212Pb]VMT-α-NET and [212Pb]VMT01. Perspective Therapeutics, Inc. announced that it will present ...

Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved ...

Circle Pharma Announces Poster Presentation Highlighting the Potential of CID-078, a First-in-class Oral Cyclin A/B RxL Inhibitor, at the American Association for Cancer Research Special Conference on ...

Crinetics Pharmaceuticals, Inc. announced that eight abstracts detailing their clinical development programs will be presented at the Endocrine Society's Annual Meeting, ENDO 2025. The presentations ...

Marvell’s presentation provides a strong indication that the company is successfully executing its AI-focused strategy. The dramatic growth in data center revenue suggests that Marvell is capitalizing ...